Data as of:
LIVE
GMRE
Global Medical REIT Inc. · Real Estate - Healthcare REIT
N/A
N/A this month
VERSUS
COMPARE
ARE
Alexandria Real Estate Equities, Inc. · Real Estate - Life Science REIT
$53.30
+5.44% this month
Comparison scoreboard
MIXED SETUPAI Scorei
GMRE N/A
ARE 25.2
1Y Returni
GMRE N/A
ARE -39.05%
Fwd P/Ei
GMRE N/A
ARE -63.14
Target Up.i
GMRE N/A
ARE +3.64%
Op. Margini
GMRE N/A
ARE 17.28%
Metrics last refreshed: 9/20/2026
Quick take
GMRE vs ARE Stock Comparison: AI Score, Valuation, Performance and Upside
ARE is the dominant, large-scale leader in life science real estate with premier lab campuses in top innovation hubs, while GMRE is a much smaller, niche medical office REIT with a more modest growth profile. The comparison highlights very different scales and sub-sectors within healthcare-adjacent real estate.
GMRE vs ARE contrasts a small-cap medical office REIT against the dominant, large-scale leader in life science laboratory real estate.
Live analysis · updated 9/20/2026
GMRE and ARE are closely matched — they split the tracked metrics evenly.
Normalized 1Y performance
GMRE
ARE
Not enough data to chart yet.
Recent returns
GMRE
ARE
Analyst price targets & sentiment
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
GMRE
Price target data unavailable
N/A
ARE
Price target range
analyst mean$53.00
current price$53.30
+3.6% upside to analyst mean
Who should consider this stock?
GMRE may suit investors who:
- Want exposure to smaller-scale, niche medical office real estate
- See value in Global Medical REIT's growth potential from a smaller base
- Are comfortable with higher relative leverage and tenant concentration risk
ARE may suit investors who:
- Want exposure to the dominant leader in life science laboratory real estate
- Value Alexandria's premier locations in top biotech innovation clusters
- Believe life science real estate demand will recover from near-term oversupply pressures
Performance & AI score
| Metric | GMRE | ARE |
|---|---|---|
| AI scorei | N/A | 25.2 |
| AI ranki | N/A | #2896 |
| Latest closei | N/A | $53.30 |
| 1M returni | N/A | +5.44% |
| 6M returni | N/A | +7.63% |
| 1Y returni | N/A | -39.05% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | GMRE | ARE |
|---|---|---|
| 1Y ago | N/A | $6.09K (-39.1%) started 2025-09-18 |
| 5Y ago | N/A | $3.67K (-63.3%) started 2021-09-20 |
| 10Y ago | N/A | $9.11K (-8.9%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | GMRE | ARE |
|---|---|---|
| Market capi | N/A | $8.8B |
| Trailing P/Ei | N/A | 102.99 |
| Forward P/Ei | N/A | -63.14 |
| Price/Salesi | 3.30 | N/A |
| EV/Revenuei | N/A | 8.88 |
| Analyst targeti | N/A | $53.00 |
| Target upsidei | N/A | +3.64% |
Growth, profitability & risk
| Metric | GMRE | ARE |
|---|---|---|
| Revenue growthi | N/A | -11.90% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | N/A | +47.35% |
| Operating margini | N/A | 17.28% |
| Profit margini | N/A | -36.08% |
| ROIC proxyi | N/A | -4.08% |
| Return on equityi | N/A | -4.08% |
| Dividend yieldi | N/A | 5.81% |
| Payout ratioi | N/A | 689.47% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | -0.13 | 1.17 |
| Debt/equityi | N/A | 68.67 |
| Current ratioi | N/A | 2.35 |
| Quick ratioi | N/A | 1.98 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
GMRE max drawdowniN/A
ARE max drawdowni53.79%
GMRE max wkly dropiN/A
ARE max wkly dropi28.48%
5Y risk snapshot
GMRE max drawdowniN/A
ARE max drawdowni79.30%
GMRE max wkly dropiN/A
ARE max wkly dropi28.48%
10Y risk snapshot
GMRE max drawdowniN/A
ARE max drawdowni79.30%
GMRE max wkly dropiN/A
ARE max wkly dropi28.48%
Performance metrics by period
| Period | Metric | GMRE | ARE |
|---|---|---|---|
| 1Y | Growthi | N/A | -39.05% |
| CAGRi | N/A | -39.07% | |
| Volatilityi | N/A | 47.53% | |
| Sharpe ratioi | N/A | -0.89 | |
| Sortino ratioi | N/A | -1.13 | |
| Max drawdowni | N/A | 53.79% | |
| Current drawdowni | N/A | 39.05% | |
| Avg drawdowni | N/A | 38.45% | |
| Ulcer Indexi | N/A | 40.14% | |
| Max daily dropi | N/A | 19.17% | |
| Max wkly dropi | N/A | 28.48% | |
| 5Y | Growthi | N/A | -68.49% |
| CAGRi | N/A | -20.64% | |
| Volatilityi | N/A | 34.45% | |
| Sharpe ratioi | N/A | -0.63 | |
| Sortino ratioi | N/A | -0.84 | |
| Max drawdowni | N/A | 79.30% | |
| Current drawdowni | N/A | 72.69% | |
| Avg drawdowni | N/A | 44.67% | |
| Ulcer Indexi | N/A | 49.05% | |
| Max daily dropi | N/A | 19.17% | |
| Max wkly dropi | N/A | 28.48% | |
| 10Y | Growthi | N/A | -34.33% |
| CAGRi | N/A | -4.12% | |
| Volatilityi | N/A | 29.91% | |
| Sharpe ratioi | N/A | -0.14 | |
| Sortino ratioi | N/A | -0.19 | |
| Max drawdowni | N/A | 79.30% | |
| Current drawdowni | N/A | 72.69% | |
| Avg drawdowni | N/A | 24.48% | |
| Ulcer Indexi | N/A | 34.93% | |
| Max daily dropi | N/A | 19.17% | |
| Max wkly dropi | N/A | 28.48% |
Business comparison
| Category | GMRE | ARE |
|---|---|---|
| Company | Global Medical REIT Inc. | Alexandria Real Estate Equities, Inc. |
| Sector | Real Estate - Healthcare REIT | Real Estate |
| Industry | N/A | REIT - Office |
| Core business | Global Medical REIT is a smaller healthcare REIT that owns medical office buildings and other healthcare-related real estate, leasing properties to physician groups and healthcare systems under long-term net leases. | Alexandria Real Estate Equities is the leading life science real estate REIT, developing and owning lab and office campuses clustered in major life science innovation hubs like Boston, San Francisco, and San Diego. |
| Investor focus | Investors track Global Medical REIT's acquisition pace and cap rates, tenant credit quality, and dividend coverage given its smaller scale relative to larger healthcare REIT peers. | Investors track Alexandria's life science lab leasing demand, development pipeline progress, and occupancy trends amid a period of elevated new life science supply in some markets. |
GMRE strengths
- Focused, niche strategy targeting outpatient medical office properties
- Smaller scale provides more room for percentage-based portfolio growth
- Net lease structure with healthcare tenants provides relatively stable, predictable cash flow
ARE strengths
- Dominant position in premier life science real estate clusters with high barriers to entry
- Strong, long-standing relationships with leading biotech and pharmaceutical tenants
- Large, well-located development pipeline supports long-term growth
Risks to watch — GMRE
- Much smaller scale than larger healthcare REIT peers limits capital cost and diversification advantages
- Higher relative leverage and tighter dividend coverage than larger, better-capitalized peers
- Tenant concentration risk given smaller overall portfolio size
Risks to watch — ARE
- Life science real estate has faced near-term oversupply pressure in some major markets
- Biotech tenant funding environment directly affects lab space demand
- Larger scale and higher valuation require sustained execution to justify
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons